Cost-Effectiveness of Saxagliptin Compared To Glp-1 Analogues As An Add-On To Insulin in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective

Value Health. 2014 Nov;17(7):A347. doi: 10.1016/j.jval.2014.08.711. Epub 2014 Oct 26.

Authors

M Charokopou¹, H Vioix², B Verheggen¹, L A Eddowes³, M Griffiths⁴, Z Gabriel², K Tolley⁵, M Sibartie²

Affiliations

¹ Pharmerit International, Rotterdam, The Netherlands.
² AstraZeneca UK Ltd., Luton, UK.
³ Costello Medical Consulting Ltd., Cambridge, UK.
⁴ Costello Medical Consulting, Cambridge, UK.
⁵ Tolley Health Economics Ltd., Buxton, Derbyshire, UK.

PMID: 27200661
DOI: 10.1016/j.jval.2014.08.711

No abstract available